Clinical investigator deficiencies
A clinical investigator deficiency is a failure to meet one of the obligations FDA’s regulations place on the physician running a clinical trial, as identified at an FDA inspection. The inspector lists what they observed on a Form FDA 483, and what FDA cites goes on the inspection record as a regulation and a short description of the failure — what people usually mean by a 483 citation. The same few areas account for almost all of them. This guide goes through each: the regulation, what the deficiency looks like at a site, and how often FDA cites it.
The words: observation, citation, finding, deficiency
They overlap, and they are used loosely. An observation is the inspector’s, written on the 483 at the close of the inspection; it is not yet FDA’s position. A citation names the regulation that was not met. A finding is one cited regulation from one inspection — the unit this guide counts. Deficiency is the general word for any of them, and the one FDA’s own correspondence tends to use. None of the four is the inspection’s classification: whether an inspection is NAI, VAI or OAI is decided afterward, on the significance of what was found, not the number of findings.
How often FDA cites each area
These figures cover one part of the FDA inspection record for drug and biologic trials, fiscal years 2009 to 2026: the inspections of clinical investigators and sponsor-investigators at which FDA cited at least one finding. There were 2,414 of them, carrying 4,795 findings. An inspection can carry findings in several areas, so the shares add up to more than 100%.
| Deficiency area | Regulation | Findings | Inspections | Share of inspections with a finding |
|---|---|---|---|---|
| Conducting the study | 21 CFR 312.60 | 1,954 | 1,954 | 81% |
| Case histories | 21 CFR 312.62(b) | 1,153 | 1,153 | 48% |
| Informed consent | 21 CFR 312.60, 21 CFR part 50 | 560 | 451 | 19% |
| Control and disposition of the investigational drug | 21 CFR 312.61, 312.62(a) | 381 | 365 | 15% |
| IRB review and reporting | 21 CFR 312.66 | 302 | 271 | 11% |
| Reports to the sponsor | 21 CFR 312.64 | 178 | 169 | 7% |
| Record retention | 21 CFR 312.62(c) | 62 | 62 | 3% |
| Everything else | 205 | 132 | 5% |
Inspections where FDA cited nothing are not in these figures. “Everything else” is mostly sponsor obligations, such as 21 CFR 312.50, cited at inspections of clinical investigators. The same counts by individual regulation, for every kind of inspected party: FDA clinical investigator inspection statistics.
Conducting the study
1,954 findings on record · cited at 81% of clinical investigator inspections with a finding
21 CFR 312.60 makes the clinical investigator responsible for ensuring the investigation is conducted according to the signed investigator statement (the Form FDA 1572), the investigational plan and the regulations. It is the most-cited deficiency in every year of the record, because it is the widest: anything the protocol required that the site did not do lands here.
What it looks like: subjects enrolled who did not meet the inclusion and exclusion criteria; visits, laboratory tests or assessments missed or done outside their windows; doses given incorrectly or off schedule; prohibited concomitant medications; and a clinical investigator who did not personally conduct or supervise the study, with tasks left to staff who were not qualified or not overseen.
Case histories
1,153 findings on record · cited at 48% of clinical investigator inspections with a finding
21 CFR 312.62(b) requires adequate and accurate case histories recording all observations and other data pertinent to the investigation for each subject — the case report forms and the supporting data behind them, including signed and dated consent forms and medical records.
What it looks like: source documents that do not support what was entered on the case report forms; source documents that are missing; changes to records that are not dated, not attributed or not explained; and discrepancies between the site’s records and what was reported to the sponsor. This is the deficiency that goes to whether a site’s data can be relied on.
Informed consent
560 findings on record · cited at 19% of clinical investigator inspections with a finding
21 CFR 312.60 also requires the clinical investigator to obtain informed consent from each subject in accordance with 21 CFR part 50, which sets out how consent is obtained (50.20), what the consent document must contain (50.25) and how it is documented (50.27).
What it looks like: study procedures begun before consent was obtained; subjects consented on a version of the form the IRB had not approved, or one it had since replaced; consent forms not signed or not dated by the subject; no copy given to the subject; required elements missing from the document; and language the subject could not be expected to understand.
Control and disposition of the investigational drug
381 findings on record · cited at 15% of clinical investigator inspections with a finding
21 CFR 312.61 limits the investigational drug to subjects under the clinical investigator’s personal supervision, or that of a subinvestigator responsible to them. 21 CFR 312.62(a) requires adequate records of the drug’s disposition — dates, quantity and use by subjects — and the return or authorized disposal of unused supplies.
What it looks like: disposition records that do not reconcile with what was received, dispensed and returned; drug provided to people who were not enrolled subjects, or by people not under the clinical investigator’s supervision; and unused supplies that cannot be accounted for.
IRB review and reporting
302 findings on record · cited at 11% of clinical investigator inspections with a finding
21 CFR 312.66 requires the clinical investigator to assure that an IRB provides initial and continuing review of the study, to report promptly to the IRB all changes in the research and all unanticipated problems involving risk to human subjects or others, and to make no change without IRB approval except to eliminate an apparent immediate hazard.
What it looks like: study activity continuing after IRB approval lapsed; protocol or consent changes put into use before the IRB approved them; and unanticipated problems reported late or not at all.
Reports to the sponsor
178 findings on record · cited at 7% of clinical investigator inspections with a finding
21 CFR 312.64 covers what the clinical investigator owes the sponsor: progress reports, safety reports — serious adverse events must be reported immediately — a final report, and the financial disclosure information the sponsor needs for its own submissions.
What it looks like, almost always: safety reporting — adverse events, serious ones above all, reported to the sponsor late or not at all. It is a small area, and the one that matters most directly to a sponsor, whose own safety reporting to FDA depends on it.
Record retention
62 findings on record · cited at 3% of clinical investigator inspections with a finding
21 CFR 312.62(c) requires the clinical investigator to keep study records for two years after a marketing application for the drug is approved for the indication studied, or, if none is filed or approved, two years after the investigation is discontinued and FDA is notified. It is cited when records an inspector asks for no longer exist.
How the mix has changed
The share of clinical investigator inspections with a finding that cited each area, by period. Conducting the study and case histories have led throughout; the investigational drug and IRB reporting are cited at a much smaller share of inspections than they were; reports to the sponsor is the one area whose share has grown.
| Deficiency area | FY2009–2013 | FY2014–2018 | FY2019–2023 | FY2024–2026 |
|---|---|---|---|---|
| Conducting the study | 82% | 83% | 79% | 76% |
| Case histories | 54% | 48% | 42% | 41% |
| Informed consent | 23% | 18% | 15% | 14% |
| Control and disposition of the investigational drug | 20% | 15% | 12% | 6% |
| IRB review and reporting | 16% | 9% | 10% | 6% |
| Reports to the sponsor | 5% | 6% | 8% | 12% |
| Record retention | 3% | 2% | 2% | 2% |
| Everything else | 7% | 5% | 6% | 3% |
| Inspections with a finding | 793 | 801 | 519 | 301 |
A falling share is not proof that sites improved: what FDA inspects, and how it records what it finds, have both changed over these years.
Reading a site’s deficiencies when selecting it
A finding on a clinical investigator’s record is a fact about one inspection, not a verdict on the site. Four things decide how much weight it deserves: which area — a consent or case-history finding matters to every protocol, a drug-disposition finding matters more to some than others; how recent; whether it repeats across inspections, which is what FDA itself treats as serious; and what the site did about it. A site whose responses and corrective action plans addressed each finding, and whose next inspection was NAI, has demonstrated something a site with no inspection history has not.
Most inspections where FDA cited a deficiency did not lead to a warning letter, so a check that stops at warning letters does not see them. And FDA sends its findings to the clinical investigator, not typically to the sponsor. The findings sit in inspection records, enforcement records and documents that do not share identifiers; Clinical Precedent assembles them into one record per clinical investigator and site, which is what clinical investigator vetting reads. Where a finding touches the protocol’s own risks, the options are the usual three: ask the site for their responses and corrective action plans, visit the site before signing, or choose a site without this history.
Questions this page answers
What are the most common clinical investigator deficiencies?
Not conducting the study in accordance with the signed investigator statement and the investigational plan (21 CFR 312.60), cited at about 81% of clinical investigator inspections where FDA cited anything, and inadequate or inaccurate case histories (21 CFR 312.62(b)), at about 48%. Informed consent, investigational drug disposition records, IRB reporting and safety reports to the sponsor follow.
What is a 483 citation?
It is the regulation cited for a condition an FDA inspector observed. The inspector lists observations on a Form FDA 483 at the close of the inspection; each is tied to the regulation that was not met, such as 21 CFR 312.62(b) for case histories. The observations are the inspector’s and do not represent a final agency determination.
How many deficiencies does FDA usually cite at one clinical investigator inspection?
About 2.0 on average, across the 2,414 clinical investigator inspections on record where FDA cited at least one. Many inspections end with none at all. The number matters less than the area and whether it repeats.
Does a deficiency mean the inspection was classified OAI?
No. Most inspections with a cited deficiency are classified VAI, Voluntary Action Indicated. OAI, the most serious inspection classification FDA assigns, is reserved for objectionable conditions significant enough that correction cannot be left to the clinical investigator. The classification turns on significance, not on the number of findings.
Does the sponsor find out about a clinical investigator’s deficiencies?
Not from FDA, as a rule. FDA sends inspection findings to the clinical investigator, not typically to the sponsor, and the clinical investigator is not required to report an inspection to a sponsor unless an agreement says so. The classification and the findings FDA cited become part of FDA’s inspection record, which Clinical Precedent assembles into one record per clinical investigator, site, CRO and IRB.
Counts are aggregate and carry no identifying information. Related: Good Clinical Practice (GCP) basics · Form FDA 483 for clinical investigators · clinical investigator inspection history · OAI, VAI and NAI · inspection statistics